Jessica Jalbert, PhD

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property)

Poster(s):

• (P-574) Frequency, Characteristics, and Subsequent Treatment (Tx) of Real-world Patients (pts) Who Discontinue Hedgehog Inhibitors (HHIs) as First-line (1L) Systemic Tx for Advanced Basal Cell Carcinoma (aBCC)